Core Viewpoint - Hoth Therapeutics has been granted a significant patent by the Japan Patent Office, enhancing its intellectual property portfolio in RNA-based cancer therapeutics, particularly targeting the KIT gene associated with various cancers [1][2][4]. Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative RNA-targeted precision therapies aimed at improving patient quality of life [5]. Patent Details - The newly issued patent covers antisense oligomers that target the KIT gene, which is linked to aggressive cancers such as gastrointestinal stromal tumors, leukemia, and mastocytosis [2][4]. - The patent includes antisense RNA molecules comprising 10–50 nucleotides, Morpholino and chemically modified antisense variants, as well as pharmaceutical compositions and expression vectors [7]. Strategic Importance - The patent strengthens Hoth's position in the RNA therapeutics market and supports its global strategy, providing validation and momentum for advancing its RNA platform towards clinical applications [3][4]. - Targeting the KIT pathway with antisense technology represents a precision-driven approach that could potentially overcome traditional small molecule resistance mechanisms [4][8]. Market Implications - The patent creates opportunities for licensing and partnerships in high-growth therapeutic areas, particularly in oncology, immunology, and rare diseases [8].

Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 inOpen-Label Portion of CLEER HT-001 Phase 2a clinical Trial for Cancer EGFR Inhibitor-Induced Skin ToxicitiesKey Interim Results (Day 1–21): Patients experienced a 50% reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21. Rapid symptom relief was observed, with mean scores improving to 1.0 by Day 7. Some patients achieved complete resolution of pruritus within the 21-day period. HT-001 w ...

NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1 receptor antagonist—for its potential to reduce neuroinflammation and improve cognitiv ...

Core Insights - Hoth Therapeutics, Inc. has received an official Filing Receipt from the USPTO for a new patent application related to HT-001, its lead clinical asset [1][3] - The new patent application aims to expand the company's intellectual property portfolio and protect the unique formulation and delivery method of HT-001, which is designed to alleviate dermatologic side effects in cancer patients undergoing EGFR inhibitor therapy [2][3] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments to improve patient quality of life [4] - The company emphasizes a patient-centric approach and collaborates with scientists, clinicians, and key opinion leaders to explore therapeutics with significant potential [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-38803 HOTH THERAPEUTICS, INC. (Exact name of registrant as specified in charter) | Nevada | 82-1553794 | | --- | --- | | (State or ot ...

NEW YORK, March 26, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing first-in-class therapies for allergic and inflammatory diseases, today announced two major developments in the ongoing advancement of its proprietary antisense oligonucleotide (ASO) cancer fighting drug candidate, HT-KIT.The Company has filed amended claims with the U.S. Patent and Trademark Office for its lead ASO technology targeting MS4A6A and FcεRIβ—genes implicated in aller ...

New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, while the lower dose led to delayed but substantial cell death at 72 hours. Decreased Tumor Cell Proliferation – HT-KIT treatment inhibited cell growth and proliferation in GIST-T1 cells, as confirmed by cell count reductions and decreased fluorescence intensity in proliferation assays. ...

HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor treatments. With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expanded Access Program (EAP), commonly known as "compassionate use."NEW YORK, March 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biop ...

Core Insights - Hoth Therapeutics, Inc. has announced promising findings for its novel therapeutic candidate HT-001, a topical neurokinin 1 receptor (NK1R) antagonist, aimed at treating Epidermal Growth Factor Receptor Inhibitor-Associated Papulopustular Eruptions (EGFRi PPEs) [3][6] Group 1: Clinical Findings - A recent case study highlighted the efficacy of HT-001 2% cream in a 59-year-old patient with metastatic breast cancer, who experienced full symptom and lesion resolution after one week of treatment, with no recurrence in the following three weeks [2][5] - The patient developed pruritic, burning red papules, a known side effect of EGFR inhibitors, which were effectively treated with HT-001 [2][5] Group 2: Upcoming Presentation - Data regarding HT-001 will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, scheduled for March 7-11, 2025, emphasizing its potential as a breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities [1][4] Group 3: Company Strategy and Research - Hoth Therapeutics is conducting a Phase 2A clinical trial to evaluate the efficacy and safety of HT-001 in a broader patient population, assessing its effectiveness across varying severities of EGFRi PPEs and other dermatologic manifestations induced by EGFR inhibitors [7] - The company aims to address the significant unmet need for long-term, well-tolerated treatment options for cancer patients experiencing debilitating skin reactions [6]

Core Insights - Hoth Therapeutics has announced preclinical findings indicating that Glial Cell Line-Derived Neurotrophic Factor (GDNF) may serve as a groundbreaking treatment for obesity, demonstrating significant reductions in fat accumulation and improvements in metabolism and insulin sensitivity [2][4][6] Group 1: Study Findings - GDNF significantly reduces fat accumulation and enhances metabolism in GDNF-transgenic models, even under high-fat diet conditions [2][4] - The study shows that GDNF increases basal metabolic rate, oxygen consumption, and carbon dioxide production, leading to higher energy expenditure without changes in food intake [6][7] - GDNF inhibits fat cell formation by suppressing key genes involved in fat storage and promoting fat oxidation pathways [6][7] - Enhanced glucose tolerance and lower serum leptin levels in GDNF-tg mice indicate improved metabolic health [6][7] - GDNF prevents hepatic steatosis, a common obesity-related complication, thereby reducing the risk of fatty liver disease [6][7] Group 2: Implications for Obesity Treatment - The findings suggest a paradigm shift in obesity treatment, moving away from traditional methods focused on appetite suppression to a mechanism that enhances the body's natural ability to burn fat [3][4] - GDNF-based therapies could provide a new approach to obesity management by activating natural metabolic processes, representing a significant advancement over current anti-obesity drugs [5][6] Group 3: Future Development Plans - Hoth Therapeutics is exploring various pathways for clinical translation of GDNF-based therapies, including recombinant protein delivery, gene therapy, and small-molecule mimetics [8] - The company plans to initiate further preclinical and clinical development efforts to bring this potential therapy closer to patients [8]